Last reviewed · How we verify
Phase II Study of Imatinib Mesylate and Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with imatinib mesylate may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with imatinib mesylate works as first-line therapy in treating patients with locally advanced or metastatic pancreatic cancer.
Details
| Lead sponsor | University of Medicine and Dentistry of New Jersey |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 44 |
| Start date | 2005-09 |
| Completion | 2010-10 |
Conditions
- Pancreatic Cancer
Interventions
- gemcitabine hydrochloride
- imatinib mesylate
Primary outcomes
- Progression-free Survival — 4 years
Progression-free survival in months. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Countries
United States